BPA
MRNA icon

Beacon Pointe Advisors’s Moderna MRNA Stock Holding History

Beacon Pointe Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Sell
3,246
-940
-22% -$48.6K ﹤0.01% 1750
2026
Q1 		$213K Buy
+4,186
New +$195K ﹤0.01% 1702
2024
Q4 		– Sell
-7,425
Closed -$496K – 1250
2024
Q3 		$496K Sell
7,425
-2,167
-23% -$199K 0.01% 861
2024
Q2 		$1.14M Sell
9,592
-632
-6% -$80K 0.01% 605
2024
Q1 		$1.09M Sell
10,224
-1,337
-12% -$135K 0.01% 665
2023
Q4 		$1.15M Sell
11,561
-2,295
-17% -$193K 0.01% 624
2023
Q3 		$1.43M Buy
13,856
+1,864
+16% +$208K 0.02% 535
2023
Q2 		$1.46M Buy
11,992
+6,458
+117% +$861K 0.02% 436
2023
Q1 		$850K Buy
5,534
+3,248
+142% +$536K 0.01% 586
2022
Q4 		$411K Sell
2,286
-109
-5% -$17.8K 0.01% 756
2022
Q3 		$282K Sell
2,395
-140
-6% -$21.2K 0.01% 819
2022
Q2 		$365K Sell
2,535
-1,153
-31% -$165K 0.01% 759
2022
Q1 		$635K Sell
3,688
-701
-16% -$118K 0.01% 740
2021
Q4 		$1.11M Sell
4,389
-140
-3% -$40.9K 0.03% 362
2021
Q3 		$1.74M Sell
4,529
-2,345
-34% -$865K 0.04% 299
2021
Q2 		$1.61M Buy
6,874
+4,288
+166% +$766K 0.06% 253
2021
Q1 		$338K Sell
2,586
-1,130
-30% -$164K 0.02% 363
2020
Q4 		$389K Buy
3,716
+637
+21% +$64.4K 0.03% 320
2020
Q3 		$218K Sell
3,079
-3,478
-53% -$242K 0.02% 359
2020
Q2 		$421K Buy
+6,557
New +$359K 0.04% 258

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Beacon Pointe Advisors's MRNA Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its Moderna (MRNA) stake by 22% in Q2 2026, selling an estimated $48.6K and leaving 3,246 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Beacon Pointe Advisors first reported a position in MRNA in Q2 2020 and has held it in 20 quarters since. The position peaked at $1.74M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Beacon Pointe Advisors held 3,246 shares of Moderna worth $227K as of Q2 2026.
  • Beacon Pointe Advisors sold 940 Moderna shares in Q2 2026, an estimated $48.6K.
  • Moderna made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1750 holding.
  • Beacon Pointe Advisors first reported a position in Moderna in Q2 2020 and has held it in 20 quarters since.
  • Beacon Pointe Advisors's Moderna position peaked at $1.74M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.